| Identification | Back Directory | [Name]
Spiro[2.2]pentane-1-carbonitrile, 1-[1-[6-[(3R)-3-(1-hydroxy-1-methylethyl)-1-pyrrolidinyl]-4-pyrimidinyl]-1H-indazol-6-yl]-, (1S)- | [CAS]
2307277-93-4 | [Synonyms]
LRRK2-IN-7 Spiro[2.2]pentane-1-carbonitrile, 1-[1-[6-[(3R)-3-(1-hydroxy-1-methylethyl)-1-pyrrolidinyl]-4-pyrimidinyl]-1H-indazol-6-yl]-, (1S)- | [Molecular Formula]
C24H26N6O | [MOL File]
2307277-93-4.mol | [Molecular Weight]
414.5 |
| Chemical Properties | Back Directory | [Boiling point ]
636.0±55.0 °C(Predicted) | [density ]
1.42±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
15.07±0.29(Predicted) | [color ]
Off-white to pink |
| Hazard Information | Back Directory | [Uses]
LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase?inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes[1]. | [in vivo]
In a 7 day rat dose limiting toxicity study, LRRK2-IN-7 (compound 25) is tolerated with no significant histopathology findings up to 100 mg/kg once a day (AUCtot = 330 μM·h)[1].
In an acute (2 h) rat PK/PD study, LRRK2-IN-7 (compound 25) demonstrates a dose-dependent decrease in LRRK2 pS935 in rat brain striatum with an EC50 = 0.18 nM[1]. | [References]
[1] David A Candito, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1 H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. J Med Chem. 2022 Dec 22;65(24):16801-16817. DOI:10.1021/acs.jmedchem.2c01605 |
|
|